With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.262368-30-9,N-(4-Aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide,as a common compound, the synthetic route is as follows.
Preparation of the Final Compounds: (cr) 3-Z-[1-(4-(N-(4-methyl-piperazin-1-yl-methylcarbonyl)-N-methyl-amino)-anilino)-methylene]-6-ethylcarbamoyl-2-indolinone 160 mg 3-(1-hydroxy-methylene)-6-ethylcarbamoyl-2-indolinone (starting material VIII) and 543 mg N-[(4-methyl-piperazin-1-yl)-methylcarbonyl]-N-methyl-p-phenylendiamine are dissolved in 3 ml of tetrahydrofuran, 506 ml trimethylsilylimidazole are added and the mixture is stirred for 25 minutes at 170 C. in a microwave oven. After cooling the solvent is evaporated and the residue is purified over an aluminum oxide column (activity 2-3) with methylene chloride/ethanol (19:1) as eluant. The residue is recrystallized from ether and vacuum-dried at 80 C. Yield: 0.17 g (52% of theory), Rf value: 0.60 (aluminum oxide, methylene chloride/methanol=9:1) Melting point: 255-260 C. C26H32N6O3 Mass spectrum: m/z=477 [m+H]+, 262368-30-9
As the paragraph descriping shows that 262368-30-9 is playing an increasingly important role.
Reference：
Patent; Boehringer Ingelheim International GmbH; US2006/142373; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics